Dear Colleagues,

Alzheimer's disease (AD) accounts for most cases of dementia. AD is a complex neurodegenerative disease with potentially multifactorial etiologies such as atypical amyloid β (Aβ) deposition, neurofibrillary tangles of tau proteins inside neurons, disturbed neurotransmission, inflammation, oxidative stress, and N-methyl-D-aspartate receptor (NMDAR) dysfunction. AD has been rapidly increasing in our aging society; however, current treatments for AD remain unsatisfactory. Thus, there is an increasing need to develop novel therapies to prevent and/or slow the progression of AD. 
The “Developing novel therapies for Alzheimer’s disease” collection welcomes original research and review articles related to translating biology to novel treatments of Alzheimer’s disease, and the study of therapeutic biomarkers.

Prof. Hsien-Yuan Lane

Guest Editor

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1900 USD. Submitted manuscripts should be well formatted in good English.